Autor segons l'article: Arellano-Orden E; Romero-Romero B; Sánchez-López V; Martín-Juan J; Rodríguez-Panadero F; Otero-Candelera R
Departament: Medicina i Cirurgia
Autor/s de la URV: Porras Ledantes, Jose Antonio
Paraules clau: Talc pleurodesis Survivin Survival Pleurodesis Metaanalysis Mesothelioma cells Malignant pleural effusion Lung-cancer Induction Expression Diagnostic-value Bcl-2 Apoptosis survival pleurodesis malignant pleural effusion
Resum: © 2018 Stichting European Society for Clinical Investigation Journal Foundation Background: Survivin is a well-known member of the inhibitor of apoptosis family, and has been related to increased tumour aggressivity, both in tissue and in pleural fluid. Objectives: In patients with malignant pleural effusion, we sought to investigate the changes in pleural fluid survivin concentrations induced by talc instillation into the pleural space. Those changes were also examined in relation to pleurodesis outcome and patient survival. Methods: We investigated 84 patients with malignant pleural effusion who underwent talc pleurodesis. Of them, 32 had breast cancer, 25 lung cancer and 27 had mesothelioma. Serial samples of pleural fluid were obtained before thoracoscopy (baseline) and 24 hours thereafter. Results: Survivin levels were successfully quantified in all pleural fluid samples, and they were significantly higher in samples obtained after thoracoscopic talc poudrage compared with baseline (P <.001). Patients with higher pleural fluid survivin levels at baseline had a significantly poorer pleurodesis outcome (P =.004). A 30 pg/mL cut-off for baseline survivin in pleural fluid predicted failure of pleurodesis with a 54% sensitivity and 79% specificity (P =.009). Moreover, median postpleurodesis survival of patients with baseline survivin levels ≥30 pg/mL was 4 months (range: 0.1-38), compared with 13 months (range: 0.1-259) in patients below that cut-off (P <.001). Conclusion: Elevated pleural fluid survivin concentrations are useful to predict failure of pleurodesis and are associated with shorter survival in patients with malignant pleural effusion.
Àrees temàtiques: Saúde coletiva Odontología Nutrição Medicine, research & experimental Medicine, general & internal Medicine (miscellaneous) Medicina ii Medicina i Interdisciplinar General medicine Farmacia Educação física Clinical biochemistry Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biochemistry
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 00142972
Adreça de correu electrònic de l'autor: joseantonio.porras@urv.cat
Identificador de l'autor: 0000-0001-6418-1822
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
Enllaç font original: https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.12895
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: European Journal Of Clinical Investigation. 48 (4):
Referència de l'ítem segons les normes APA: Arellano-Orden E; Romero-Romero B; Sánchez-López V; Martín-Juan J; Rodríguez-Panadero F; Otero-Candelera R (2018). Survivin is a negative prognostic factor in malignant pleural effusion. European Journal Of Clinical Investigation, 48(4), -. DOI: 10.1111/eci.12895
DOI de l'article: 10.1111/eci.12895
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2018
Tipus de publicació: Journal Publications